US 12,433,881 B2
Nicotine tablet
Bruno Provstgaard Nielsen, Vejle Øst (DK); and Kent Albin Nielsen, Brande (DK)
Assigned to Fertin Pharma A/S, Vejle (DK)
Filed by Fertin Pharma A/S, Vejle (DK)
Filed on Apr. 29, 2024, as Appl. No. 18/649,759.
Application 18/649,759 is a continuation of application No. 18/348,891, filed on Jul. 7, 2023, granted, now 12,005,058.
Application 18/348,891 is a continuation of application No. 16/213,641, filed on Dec. 7, 2018, granted, now 11,738,016.
Claims priority of application No. PA 2017 70925 (DK), filed on Dec. 8, 2017.
Prior Publication US 2024/0285610 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/465 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61P 25/34 (2006.01)
CPC A61K 31/465 (2013.01) [A61K 9/0056 (2013.01); A61K 9/006 (2013.01); A61K 9/2009 (2013.01); A61K 9/2027 (2013.01); A61K 9/2095 (2013.01); A61P 25/34 (2018.01)] 24 Claims
 
1. An orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, wherein the tablet disintegrates within a period of less than 210 seconds upon oral administration, wherein the pressed powder formulation comprises an amount of nicotine, a pH regulating agent, at least one polyol, and a disintegrant, wherein the tablet comprises the polyol in an amount of more than 40% by weight of the tablet, wherein the disintegrant comprises superdisintegrant in an amount of 1 to 10% by weight of the tablet, wherein the formulation provides a peak saliva pH of more than 7.6 during the first 120 seconds upon oral administration, and wherein the tablet reduces the side effect of burning.